|
|
|
|
|
|
|
|
|
|
Immunotherapy for Ovarian Cancer - CRI
Checkpoint Inhibitors and Immune Modulators
Another promising avenue of clinical research in ovarian cancer is the use of checkpoint inhibitors and immune modulators. These treatments work by targeting molecules that serve as checks and balances in the regulation of immune responses. By blocking inhibitory molecules or, alternatively, activating stimulatory molecules, these treatments are designed to unleash or enhance pre-existing anti-cancer immune responses.
Ipilimumab (Yervoy®), which targets the CTLA-4 checkpoint molecule on activated immune cells, is being tested in a variety of cancer types, including ovarian cancer, for which a phase II study (NCT01611558) is currently under way.
MEDI4736, an anti-PD-L1 checkpoint inhibitor made by MedImmune/AstraZeneca, is being tested in a number of trials:
A phase I/II trial of MEDI4736 for patients with solid tumors (NCT01693562).
A phase I/II trial of MEDI6469, an anti-OX40 agonist antibody, alone or with tremelimumab, an anti-CTLA-4 antibody, and/or MEDI4736 (NCT02205333).
A phase I trial of MEDI0680 (AMP-514), an anti-PD-1 antibody, and MEDI4736 in patients with advanced cancers (NCT02118337).
MEDI4736 and tremelimumab are being tested in two trials. One is a phase I trial sponsored by MedImmune for patients with solid tumors (NCT02261220). The other is a phase I trial, sponsored by Ludwig Cancer Research in collaboration with CRI and MedImmune, in patients with advanced solid tumors, including ovarian cancer (NCT01975831).
A phase Ib trial to test pembrolizumab (Keytruda®, MK-3475), an anti-PD-1 antibody being developed by Merck, in patients with advanced, biomarker-positive solid tumors (NCT02054806).
Two phase I trials to test MPDL3280A, an anti-PD-L1 antibody being developed by Roche/Genentech, in patients with several cancers (NCT01375842, NCT01633970).
A phase I trial testing urelumab (BMS-663513), an anti-4-1BB/CD137 antibody made by Bristol-Myers Squibb, in patients with advanced cancers (NCT01471210). Another phase I/II trial of urelumab given along with nivolumab (anti-PD-1) in patients with solid tumors (NCT02253992).
A phase I trial to test PF-05082566, an anti-4-1BB/CD137 antibody developed by Pfizer, in patients with solid tumors (NCT01307267).
A phase I study of lirilumab, an anti-KIR antibody being developed by Bristol-Myers Squibb, in combination with nivolumab (anti-PD-1) in patients with advanced solid tumors (NCT01714739).
A phase I trial to test BMS-986016, a LAG-3 antibody, with or without nivolumab (anti-PD-1) in patients with solid tumors (NCT01968109).
A pilot study to test INCB024360, an IDO1 inhibitor, in patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer (NCT02042430).
Checkpoint Inhibitors and Immune Modulators
Another promising avenue of clinical research in ovarian cancer is the use of checkpoint inhibitors and immune modulators. These treatments work by targeting molecules that serve as checks and balances in the regulation of immune responses. By blocking inhibitory molecules or, alternatively, activating stimulatory molecules, these treatments are designed to unleash or enhance pre-existing anti-cancer immune responses.
Another promising avenue of clinical research in ovarian cancer is the use of checkpoint inhibitors and immune modulators. These treatments work by targeting molecules that serve as checks and balances in the regulation of immune responses. By blocking inhibitory molecules or, alternatively, activating stimulatory molecules, these treatments are designed to unleash or enhance pre-existing anti-cancer immune responses.
- Ipilimumab (Yervoy®), which targets the CTLA-4 checkpoint molecule on activated immune cells, is being tested in a variety of cancer types, including ovarian cancer, for which a phase II study (NCT01611558) is currently under way.
-
MEDI4736, an anti-PD-L1 checkpoint inhibitor made by MedImmune/AstraZeneca, is being tested in a number of trials:
- A phase I/II trial of MEDI4736 for patients with solid tumors (NCT01693562).
- A phase I/II trial of MEDI6469, an anti-OX40 agonist antibody, alone or with tremelimumab, an anti-CTLA-4 antibody, and/or MEDI4736 (NCT02205333).
- A phase I trial of MEDI0680 (AMP-514), an anti-PD-1 antibody, and MEDI4736 in patients with advanced cancers (NCT02118337).
- MEDI4736 and tremelimumab are being tested in two trials. One is a phase I trial sponsored by MedImmune for patients with solid tumors (NCT02261220). The other is a phase I trial, sponsored by Ludwig Cancer Research in collaboration with CRI and MedImmune, in patients with advanced solid tumors, including ovarian cancer (NCT01975831).
- A phase Ib trial to test pembrolizumab (Keytruda®, MK-3475), an anti-PD-1 antibody being developed by Merck, in patients with advanced, biomarker-positive solid tumors (NCT02054806).
- Two phase I trials to test MPDL3280A, an anti-PD-L1 antibody being developed by Roche/Genentech, in patients with several cancers (NCT01375842, NCT01633970).
- A phase I trial testing urelumab (BMS-663513), an anti-4-1BB/CD137 antibody made by Bristol-Myers Squibb, in patients with advanced cancers (NCT01471210). Another phase I/II trial of urelumab given along with nivolumab (anti-PD-1) in patients with solid tumors (NCT02253992).
- A phase I trial to test PF-05082566, an anti-4-1BB/CD137 antibody developed by Pfizer, in patients with solid tumors (NCT01307267).
- A phase I study of lirilumab, an anti-KIR antibody being developed by Bristol-Myers Squibb, in combination with nivolumab (anti-PD-1) in patients with advanced solid tumors (NCT01714739).
- A phase I trial to test BMS-986016, a LAG-3 antibody, with or without nivolumab (anti-PD-1) in patients with solid tumors (NCT01968109).
- A pilot study to test INCB024360, an IDO1 inhibitor, in patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer (NCT02042430).
Checkpoint Inhibitors and Immune Modulators
Another promising avenue of clinical research in ovarian cancer is the use of checkpoint inhibitors and immune modulators. These treatments work by targeting molecules that serve as checks and balances in the regulation of immune responses. By blocking inhibitory molecules or, alternatively, activating stimulatory molecules, these treatments are designed to unleash or enhance pre-existing anti-cancer immune responses.
Another promising avenue of clinical research in ovarian cancer is the use of checkpoint inhibitors and immune modulators. These treatments work by targeting molecules that serve as checks and balances in the regulation of immune responses. By blocking inhibitory molecules or, alternatively, activating stimulatory molecules, these treatments are designed to unleash or enhance pre-existing anti-cancer immune responses.
- Ipilimumab (Yervoy®), which targets the CTLA-4 checkpoint molecule on activated immune cells, is being tested in a variety of cancer types, including ovarian cancer, for which a phase II study (NCT01611558) is currently under way.
-
MEDI4736, an anti-PD-L1 checkpoint inhibitor made by MedImmune/AstraZeneca, is being tested in a number of trials:
- A phase I/II trial of MEDI4736 for patients with solid tumors (NCT01693562).
- A phase I/II trial of MEDI6469, an anti-OX40 agonist antibody, alone or with tremelimumab, an anti-CTLA-4 antibody, and/or MEDI4736 (NCT02205333).
- A phase I trial of MEDI0680 (AMP-514), an anti-PD-1 antibody, and MEDI4736 in patients with advanced cancers (NCT02118337).
- MEDI4736 and tremelimumab are being tested in two trials. One is a phase I trial sponsored by MedImmune for patients with solid tumors (NCT02261220). The other is a phase I trial, sponsored by Ludwig Cancer Research in collaboration with CRI and MedImmune, in patients with advanced solid tumors, including ovarian cancer (NCT01975831).
- A phase Ib trial to test pembrolizumab (Keytruda®, MK-3475), an anti-PD-1 antibody being developed by Merck, in patients with advanced, biomarker-positive solid tumors (NCT02054806).
- Two phase I trials to test MPDL3280A, an anti-PD-L1 antibody being developed by Roche/Genentech, in patients with several cancers (NCT01375842, NCT01633970).
- A phase I trial testing urelumab (BMS-663513), an anti-4-1BB/CD137 antibody made by Bristol-Myers Squibb, in patients with advanced cancers (NCT01471210). Another phase I/II trial of urelumab given along with nivolumab (anti-PD-1) in patients with solid tumors (NCT02253992).
- A phase I trial to test PF-05082566, an anti-4-1BB/CD137 antibody developed by Pfizer, in patients with solid tumors (NCT01307267).
- A phase I study of lirilumab, an anti-KIR antibody being developed by Bristol-Myers Squibb, in combination with nivolumab (anti-PD-1) in patients with advanced solid tumors (NCT01714739).
- A phase I trial to test BMS-986016, a LAG-3 antibody, with or without nivolumab (anti-PD-1) in patients with solid tumors (NCT01968109).
- A pilot study to test INCB024360, an IDO1 inhibitor, in patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer (NCT02042430).
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.